

EUPROMS study

EUROPA UOMO patient reported outcome study

The first ever survey in PCa from patients for patients

André Deschamps Ing. MBA
Chairman

EUROPA UOMO 

The Voice of Men with Prostate Cancer in Europe

Disclosures

- Sponsored by 3 pharmaceutical companies.
- They have had no role or influence in any aspect of the study and this will remain the position




EUPROMS study

Methodology and sample profiles

EUROPA UOMO 

The Voice of Men with Prostate Cancer in Europe

Methodology



20 minute online survey with patients with prostate cancer who have received treatment

Objective

- Examine the quality of life of PCa patients Europe wide
- Use of validated quality of life questionnaires
 - EPIC 26
 - EORTC
 - EQ-5D-5L

Recruitment and data collection

- Via a link placed on the Europa Uomo website
- Actively circulated by members of Europa Uomo
- Data collected by Cellohealth UK



Observational single arm study

Patient screening criteria

- Male with prostate cancer
- Receiving or have received some treatment for their prostate cancer, including active surveillance
- Not affiliated in any way with a pharmaceutical company
- Not participated in related research in the past month


Languages

- Questionnaire available in 19 languages

Geographic coverage and valid answers

2943
answers

24 countries



Austria	66
Belgium	339
Bulgaria	1
Czech Republic	3
Denmark	188
Estonia	8
Finland	65
France	234
Germany	253
Greece	1
Hungary	10
Ireland	26
Italy	71
Latvia	11
Lithuania	52
Norway	506
Poland	109
Portugal	75
Slovak Republic	8
Spain	55
Sweden	386
Switzerland	7
The Netherlands	244
UK	187
Other (mainly Cyprus)	38

1,22 per
1000


1,22 per 1000 patients
out of 2,4 Million (estimated) have
answered the questionnaire

5 years prevalence 1,3 million*
*Source centre for parliamentary studies eu


10 years prevalence 2,4 million**
**Calculated based on know figures for some countries

Respondence profile:


Current age




Age at Diagnosis




Living situation



Employment




Education




Treatments profile

Amount of treatments




- 1
- 2
- 3
- 4 or more

Treatment = 1



Treatment = 2




EUPROMS study

EORTC, EQ-5D-5L and EPIC first results


EUROPA UOMO 

The Voice of Men with Prostate Cancer in Europe

EORTC functional score



EORTC symptom score



2nd treatment and cancer recurrence = worse scores overall


EQ-5D-5L

Total EQ-5D-5L Score

61

73


77



Mental health is impacted: 45% reporting at least some anxiety/depression


EPIC scores

Sexual function is the most impacted area



This **28** sexual score is much lower than other studies

Sexual Function after Prostate SBRT



THE JOURNAL OF
SEXUAL MEDICINE

ORIGINAL RESEARCH & REVIEWS

ONCOLOGY


Sexual Function in Patients Treated With Stereotactic Radiotherapy
For Prostate Cancer: A Systematic Review of the Current Evidence

[Check for updates](#)

Mauro Loi, MD,¹ Ruud C. Wortel, MD, PhD,² Giulio Francolini, MD,¹ and Luca Incrocci, MD, PhD³


50% report that sexual function is a moderate or big problem

- Big problem
- Moderate problem
- Small problem
- Very small problem




EPIC sexual function: use of medication

Only 34% have used medication or devices



EPIC sexual function: satisfaction with medication or device



Key messages so far

- **The collected data** are representative for the patient population
- **Sexual function** is the major effect of all PCA treatments.
The measured score is much lower than expected
- **Fatigue, insomnia and anxiety/depression** are other important effects
- Patients who are receiving their **2nd or later treatment due to cancer recurrence** have worse scores across all metrics

Next steps

- **Analyse** results further

Partner Prof. Monique Roobol, Erasmus University Medical center, Department of Urology, Rotterdam , NL

- **Publish** results and awareness campaign

- **Update** EAU in Amsterdam

Next steps budget

- **Analyse** results further 15 000 €
- **Publish** results at booth EAU 10 000 €